Clinical trials
Relapsed or Refractory B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,718 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07223840RecruitingPhase 2
A study of brenipatide to help former smokers stay smoke-free
This trial tests an injectable drug called brenipatide to see if it helps people who have recently quit smoking stay quit for good. The study follows participants over time and requires them to come to clinic visits.
Rogers, ArkansasAges 18–75 - NCT07227818RecruitingPhase 3
Testing NBI-1117568 to prevent schizophrenia relapse
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
Garden Grove, CaliforniaAges 18–65 - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
San Francisco, CaliforniaAges 6 months–25 years - NCT05365672RecruitingPhase 2
Donor immune cell therapy during live kidney transplant
This Phase 2 trial studies a treatment using immune cells made from your living donor, given around the time of kidney transplant. It aims to improve transplant safety and outcomes by adjusting the immune response to the new kidney.
BerlinAges 18–69 - NCT07208981RecruitingPhase 2
Orelabrutinib, zebetuzumab, and lenalidomide for new MZL
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
Nanjing, JiangsuAges 18–75 - NCT05956457Recruiting
Using wearable and PRO check-ins for relapsed myeloma
This study uses your self-reported symptoms (PRO) and wearable/device data to help improve care for people with relapsed multiple myeloma who are starting new treatment. It may help by providing insights about how you’re doing during therapy—without changing your cancer treatment in a study-specific way.
Seattle, WashingtonAges 18 years+ - NCT06297941RecruitingPhase 1
Study of REM-422 for AML or high-risk MDS
This trial tests an experimental oral medication called REM-422 for people with AML (a type of blood cancer) that has not responded to treatment or has come back, or for those with high-risk MDS. The goal is to see if it is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07195799RecruitingPhase 2
Linperlisib with CPT for relapsed or refractory non-Hodgkin lymphoma
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
Nanjing, JiangsuAges 18 years+ - NCT07193823Recruiting
Sexual function study for women with MS
This study looks at sexual health in women with relapsing-remitting multiple sclerosis. It aims to understand how MS might affect sexual function and to find ways to help.
Izmir, BornovaAges 25–50 - NCT07184853Recruiting
Ruxolitinib with etanercept vs ruxolitinib for severe GVHD
This trial tests whether adding etanercept to ruxolitinib works better than ruxolitinib alone for severe graft-versus-host disease (GVHD) that has not responded to steroids. GVHD is a common complication after a stem cell transplant where donor cells attack the patient's body.
Hangzhou, ZhejiangAges 12–70 - NCT07185373RecruitingPhase 2/Phase 3
Newly diagnosed CNS lymphoma with orelabrutinib combination therapy
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
BeijingAges 18–75 - NCT06105853Recruiting
Stress and brain activity in alcohol use disorder
This study looks at how people with alcohol use disorder respond to stress and what happens in the brain. You'll use a smartphone and may have an MRI scan to understand your stress responses.
Mannheim, Baden-WurttembergAges 18–65 - NCT07180693Recruiting
Breast cancer that returns after CDK4/6 inhibitor treatment
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
Bergamo, ItalyAges 18 years+ - NCT07179679RecruitingPhase 1
Study of a new shot for multiple myeloma
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06643585RecruitingPhase 3
Comparing T-DXd to standard therapy for molecular relapse in early breast cancer
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
UlmAges 18–75 - NCT07154823Recruiting
Blood cancer registry study for biomarker discovery
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Iowa City, IowaAges birth+ - NCT06956326RecruitingPhase 2
Early rehab for multiple sclerosis relapse recovery
This trial tests whether early and specialized rehabilitation can help people with multiple sclerosis recover better after a motor relapse. It is for people who are already staying at a Danish MS Hospital for rehab.
HaslevAges 18 years+ - NCT07139873RecruitingPhase 3
Study of DZD8586 vs. standard care for relapsed CLL or SLL
This trial tests a new drug, DZD8586, against other standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior therapy. The goal is to see if DZD8586 works better or has fewer side effects.
Nanjing, JiangsuAges 18 years+ - NCT07139067RecruitingPhase 1
YK1101 for advanced solid tumors
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
BeijingAges 18–75 - NCT06819670RecruitingPhase 2
Preventing infantile spasms from coming back
This trial tests whether a longer course of steroids can keep infantile spasms from returning in babies who have already responded to standard treatment. It may help reduce the chance of relapse.
Los Angeles, CaliforniaAges 2 months–1.5 years - NCT07129642RecruitingEarly Phase 1
Donor CAR-T cells for hard-to-treat Graves' disease
This trial tests a new type of cell therapy called CAR-T cells made from a donor. The cells target B cells that may drive Graves' disease. It's for people whose Graves' disease has not gotten better with usual treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07125794Recruiting
Brace comparison for children with relapsed clubfoot
This trial tests whether a modified version of the Denis Brawn brace works better than the original for treating relapsed clubfoot in young children who were previously treated with the Ponseti casting method.
CairoAges 2–5
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell lymphoma?
- Yes. Clin2 currently lists 1,718 recruiting relapsed or refractory b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- Relapsed or Refractory Peripheral T Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.